Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5828 USD | +3.26% | -2.08% | +7.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.27% | 121M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.11% | 22.48B | |
-9.63% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024